All Stories

  1. Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial
  2. Does Gender Diversity Promote Nonconformity?
  3. Common genetic variants associated with cognitive performance identified using the proxy-phenotype method
  4. Linking Genes and Political Orientations: Testing the Cognitive Ability as Mediator Hypothesis
  5. The Relationship between Genes, Psychological Traits, and Political Participation
  6. Discrimination against students with foreign backgrounds: evidence from grading in Swedish public high schools
  7. Genetic Influences on Political Ideologies: Twin Analyses of 19 Measures of Political Ideologies from Five Democracies and Genome-Wide Findings from Three Populations
  8. Pre-Birth Factors, Post-Birth Factors, and Voting: Evidence from Swedish Adoption Data
  9. The co-twin methodology and returns to schooling — testing a critical assumption
  10. The heritability of moral standards for everyday dishonesty
  11. Swedish experience-based value sets for EQ-5D health states
  12. Intuition and cooperation reconsidered
  13. GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational Attainment
  14. Molecular genetics and subjective well-being
  15. Gender differences in social framing effects
  16. The Swedish Twin Registry: Establishment of a Biobank and Other Recent Developments
  17. Genetic and Environmental Influences on the Relationship between Flow Proneness, Locus of Control and Behavioral Inhibition
  18. Do people care about social context? Framing effects in dictator games
  19. Most Reported Genetic Associations With General Intelligence Are Probably False Positives
  20. Social framing effects: Preferences or beliefs?
  21. The Promises and Pitfalls of Genoeconomics
  22. Does parametric fMRI analysis with SPM yield valid results?—An empirical study of 1484 rest datasets
  23. The genetic architecture of economic and political preferences
  24. The Genetic Origins of the Relationship between Psychological Traits and Social Trust
  25. The Behavioral Genetics of Behavioral Anomalies
  26. Molecular Genetics and Economics
  27. Conspicuous generosity
  28. Are boys discriminated in Swedish high schools?
  29. Limbic Justice—Amygdala Involvement in Immediate Rejection in the Ultimatum Game
  30. Regional differences in health status in China: Population health-related quality of life results from the National Health Services Survey 2008
  31. A randomized trial of the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal women
  32. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008
  33. The Effect of Competition on Physical Activity: A Randomized Trial
  34. Genetic Variation in Financial Decision‐Making
  35. On the sources of the height–intelligence correlation: New insights from a bivariate ACE model with assortative mating
  36. No Association between Oxytocin Receptor (OXTR) Gene Polymorphisms and Experimentally Elicited Social Preferences
  37. Anchoring and cognitive ability
  38. Testing guilt aversion
  39. Time is not money
  40. Higher cognitive ability is associated with lower entries in a p-beauty contest
  41. Bargaining over a Common Good with Private Information*
  42. Experimental Game Theory and Behavior Genetics
  43. The aversion to lying
  44. Genetic Variation in Preferences for Giving and Risk Taking *
  45. A randomized trial of the effect of estrogen and testosterone on economic behavior
  46. Heritability of Overconfidence
  47. Trust and Truth
  48. Eliciting Willingness to Pay without Bias using Follow-up Certainty Statements: Comparisons between Probably/Definitely and a 10-point Certainty Scale
  49. Crowding Out in Blood Donation: Was Titmuss Right?
  50. Pride and Prejudice: The Human Side of Incentive Theory
  51. Gender differences in deception
  52. Heritability of cooperative behavior in the trust game
  53. Communication: Content or relationship?
  54. Anticipated verbal feedback induces altruistic behavior
  55. Eliciting Willingness to Pay Without Bias: Evidence from a Field Experiment
  56. Paying Respect
  57. Heritability of ultimatum game responder behavior
  58. Deteriorating health status in Stockholm 1998–2002: results from repeated population surveys using the EQ-5D
  59. Is Altruism Paternalistic?
  60. Is generosity involuntary?
  61. Confidence interval estimation tasks and the economics of overconfidence
  62. Consumption and Health
  63. A comparison of individual and social time trade-off values for health states in the general population
  64. Increasing socio‐economic inequalities in life expectancy and QALYs in Sweden 1980–1997
  65. Sunk costs and fairness in incomplete information bargaining
  66. Business cycles and mortality: results from Swedish microdata
  67. Is There a Hold‐up Problem?
  68. Promises, Threats and Fairness
  69. Absolute Income, Relative Income, Income Inequality, and Mortality
  70. Health State Utilities in Gastroesophageal Reflux Disease Patients with Heartburn: A Study in Germany and Sweden
  71. A note on the effect of unemployment on mortality
  72. Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies
  73. Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies
  74. On the measurement of relative and absolute income-related health inequality
  75. The value of the change in health in Sweden 1980/81 to 1996/97
  76. Assessment of the Relationship Between Measures of Disease Severity, Quality of Life, and Willingness to Pay in Asthma
  77. The relationship between happiness, health, and socio-economic factors: results based on Swedish microdata
  78. Should we aggregate relative or absolute changes in QALYs?
  79. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
  80. Hypothetical versus real willingness to pay in the health care sector: results from a field experiment
  81. Time Preference for Health: A Test of Stationarity versus Decreasing Timing Aversion
  82. Health-related quality of life by disease and socio-economic group in the general population in Sweden
  83. Non-reciprocal altruism in dictator games
  84. Income-related inequality in life-years and quality-adjusted life-years
  85. Health-related Quality of Life in Patients with Psoriasis and Atopic Dermatitis Measured with SF-36, DLQI and a Subjective Measure of Disease Activity
  86. Resource Utilization and Costs of Stroke Unit Care Integrated in a Care Continuum: A 1-Year Controlled, Prospective, Randomized Study in Elderly Patients
  87. New estimates of the demand for health: results based on a categorical health measure and Swedish micro data
  88. A comparison of patient and social tariff values derived from the time trade-off method
  89. Use of contingent valuation to place a monetary value on pharmacy services: An overview and review of the literature
  90. On aggregating QALYs: a comment on Dolan
  91. Probability Weighting and Utility Curvature in QALY-Based Decision Making
  92. Cost Benefit of Treating Hypertension
  93. Urge Incontinence
  94. Time spent on waiting lists for medical care: an insurance approach
  95. An experimental test of question framing in health state utility assessment
  96. The Impact of Risk Information on Patients' Willingness to Pay for Autologous Blood Donation
  97. Experimental Results on Expressed Certainty and Hypothetical Bias in Contingent Valuation
  98. Cost-effectiveness analysis and capital costs
  99. Effects of user charges on the use of prescription medicines in different socio-economic groups
  100. An experimental comparison of dichotomous choice contingent valuation questions and real purchase decisions
  101. Editorial: Some reflections on cost-effectiveness analysis
  102. Relationship Between Quality of Life Instruments, Health State Utilities, and Willingness to Pay in Patients with Asthma
  103. The Effect of Changes in Treatment Patterns on Drug Expenditure
  104. A Note on Confidence Intervals in Cost-Effectiveness Analysis
  105. Price Indices of Drugs and the Switching to New Drugs
  106. Contingent valuation with an open‐ended follow‐up question: a test of scope effects
  107. Contingent valuation with an open-ended follow-up question: a test of scope effects
  108. Hypothetical versus real payments in Vickrey auctions
  109. Is the valuation of a QALY gained independent of age? Some empirical evidence
  110. The impact of hormone replacement therapy on quality of life and willingness to pay
  111. A note on prevention versus cure
  112. Cost-utility analysis and varying preferences for health
  113. Some further experimental results on hypothetical versus real willingness to pay
  114. The cost-effectiveness of a cardiovascular risk reduction program in general practice
  115. Quality of life and the WTP for an increased life expectancy at an advanced age
  116. Avoiding Double-Counting in Pharmacoeconomic Studies
  117. The friction cost method: A comment
  118. Patients' willingness to pay for autologous blood donation
  119. Standard gamble, time trade-off and rating scale: Experimental results on the ranking properties of QALYs
  120. Cost-utility analysis from a societal perspective
  121. Hypothetical versus real willingness to pay: some experimental results
  122. Cost Effectiveness of Simvastatin Treatment to Lower Cholesterol Levels in Patients with Coronary Heart Disease
  123. The value of life extension and the marginal rate of time preference: a pilot study
  124. Cost-benefit analysis of lipid lowering therapy
  125. Valuation of health changes with the contingent valuation method: A test of scope and question order effects
  126. The value of private safety versus the value of public safety
  127. Valuation of health changes with the contingent valuation method: A test of scope and question order effects
  128. The economics of ageing: on the attitude of Swedish people to the distribution of health care resources between the young and the old
  129. To be, or not to be, that is the question: An empirical study of the WTP for an increased life expectancy at an advanced age
  130. Economic Evaluation in Healthcare
  131. Outcome measurement in economic evaluation
  132. Outcome measurement in economic evaluation
  133. The cost effectiveness of lipid lowering in Swedish primary health care
  134. Cost-effectiveness of cholesterol lowering: Results from the Scandinavian Simvastatin Survival Study (4S)
  135. The willingness to pay for health changes, the human-capital approach and the external costs
  136. The Impact of User Charges on the Consumption of Drugs
  137. A note on the estimation of the equity-efficiency trade-off for QALYs
  138. Incorporating quality of life changes into economic evaluations of health care: an overview
  139. The Decision Rules of Cost-Effectiveness Analysis
  140. Use of Misoprostol in the Elderly
  141. A note on the relationship between ex ante and expected willingness to pay for health care
  142. Theory and Methods of Economic Evaluation of Health Care
  143. Welfare Economics
  144. Additional Issues in Cost-Benefit Analysis
  145. Cost-Effectiveness Analysis
  146. Concluding Remarks
  147. The Estimation of Costs
  148. Economic Evaluation and Policy Making
  149. The Monetary Value of Health Changes
  150. Cost-Utility Analysis
  151. The Expressed Preference Approach
  152. The Resource Consequences of Health Changes
  153. Introduction
  154. The Revealed Preference Approach
  155. Value for money? A contingent valuation study of the optimal size of the Swedish health care budget
  156. A pilot test of using the veil of ignorance approach to estimate a social welfare function for income
  157. Economic Evaluation of Drugs and its Potential Uses in Policy Making
  158. The relationship between cost-effectiveness analysis and cost-benefit analysis
  159. Has the Cost-effectiveness of Misoprostol Been Underestimated?-Reply
  160. A note on the depreciation of the societal perspective in economic evaluation of health care
  161. Quality-adjusted life-years versus healthy-years equivalents — A comment
  162. On the estimation of cost-effectiveness ratios
  163. The Cost Effectiveness of Hypertension Treatment in Sweden
  164. Qalys: A comment
  165. The Ranking Properties of Healthy-Years Equivalents and Quality-Adjusted Life-Years Under Certainty and Uncertainty
  166. The costs and effects of two different lipid intervention programmes in primary health care
  167. The cost‐effectiveness of a cardiovascular multiple‐risk‐factor intervention programme in treated hypertensive men
  168. QALYs, HYEs and individual preferences— A graphical illustration
  169. The cost-effectiveness of the switch towards more expensive antihypertensive drugs
  170. The Concept of Cost in the Economic Evaluation of Health Care:A Theoretical Inquiry
  171. The contingent valuation method—appraising the appraisers
  172. On the decision rules of cost-effectiveness analysis
  173. 98 The cost-effectiveness of treating hypertension in the elderly
  174. Drug Expenditure and New Drug Introductions
  175. The cost‐effectiveness of treating hypertension in elderly people—an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension)
  176. Economic evaluation of osteoporosis prevention
  177. Willingness to pay for antihypertensive therapy — further results
  178. Cost-Effectiveness of Antihypertensive Treatment
  179. The Australian Guidelines for Subsidisation of Pharmaceuticals
  180. A health-economic comparison of diet and drug treatment in obese men with mild hypertension
  181. Economic Evaluation of Drug Therapy
  182. A Review of Cost-Effectiveness Analyses of Hypertension Treatment
  183. Economic evaluation of lipid lowering — A feasibility test of the contingent valuation approach
  184. On the Discounting of Gained life-Years in Cost-Effectiveness Analysis
  185. Economic Evaluation of Hypertension Treatment
  186. Cost‐benefit analysis of non‐pharmacological treatment of hypertension
  187. Cost-effectiveness analysis of hypertension treatment — A review of methodological issues
  188. The costs of treating hypertension — an analysis of different cut-off points
  189. Economic evaluation in health care: Is there a role for cost-benefit analysis?
  190. Comment on “dealing With Discounting”
  191. The Costs of Treating Hypertension in Sweden
  192. Willingness to pay for antihypertensive therapy — results of a Swedish pilot study
  193. Do People Care About Social Context? Framing Effects in Dictator Games
  194. The determinants of health in Sweden
  195. Generosity and Political Preferences
  196. The Co-Twin Methodology and Returns to Schooling - Testing a Critical Assumption
  197. Eliciting Willingness to Pay Without Bias Using Follow-Up Certainty Statements: Comparisons Between Probably/Definitely and a 10-Point Certainty Scale